The Biosynthesis, Fate and Pharmacological Properties of Endocannabinoids 173- To carry on identifying those disorders that can be caused, at least in part, by
a malfunctioning endocannabinoid system, or whose onset, progress and/or
symptoms are counteracted tonically by the endocannabinoids
Once these further tasks have been achieved, and the regulation of the en-
docannabinoid system under both physiological and pathological conditions is
fully understood, it will be possible to assess whether endocannabinoid-based
medicines with clear advantages over other established therapeutic drugs could be
developed in the future.
References
Adams IB, Compton DR, Martin BR (1998) Assessment of anandamide interaction with the
cannabinoid brain receptor: SR 141716A antagonism studies in mice and autoradio-
graphic analysis of receptor binding in rat brain. J Pharmacol Exp Ther 284:1209–1217
Ahluwalia J, Urban L, Bevan S, Nagy I (2003a) Anandamide regulates neuropeptide release
from capsaicin-sensitive primary sensory neurons by activating both the cannabinoid
1 receptor and the vanilloid receptor 1 in vitro. Eur J Neurosci 17:2611–2618
Ahluwalia J, Yaqoob M, Urban L, Bevan S, Nagy I (2003b) Activation of capsaicin-sensitive
primary sensory neurones induces anandamide production and release. J Neurochem
84:585–591
Andersson DA, Adner M, Hogestatt ED, Zygmunt PM (2002) Mechanisms underlying tissue
selectivity of anandamide and other vanilloid receptor agonists. Mol Pharmacol 62:705–
713
Appendino G, Ligresti A, Minassi A, Daddario N, Bisogno T, Di Marzo V (2003) Homologues
and isomers of noladin ether, a putative novel endocannabinoid: interaction with rat
cannabinoid CB(1) receptors. Bioorg Med Chem Lett 13:43–46
Baker D, Pryce G, Croxford JL, Brown P, Pertwee RG, Huffman JW, Layward L (2000)
Cannabinoidscontrolspasticityandtremorinamultiplesclerosismodel.Nature404:84–
87
Baker D, Pryce G, Croxford JL, Brown P, Pertwee RG, Makriyannis A, Khanolkar A, Layward
L, Fezza F, Bisogno T, Di Marzo V (2001) Endocannabinoids control spasticity in a
multiple sclerosis model. FASEB J 15:300–302
Basavarajappa BS, Saito M, Cooper TB, Hungund BL (2000) Stimulation of cannabinoid
receptor agonist 2-arachidonylglycerol by chronic ethanol and its modulation by specific
neuromodulators in cerebellar granule neurons. Biochim Biophys Acta 1535:78–86
Basavarajappa BS, Saito M, Cooper TB, Hungund BL (2003) Chronic ethanol inhibits the
anandamide transport and increases extracellular anandamide levels in cerebellar gran-
ule neurons. Eur J Pharmacol 466:73–83
BatkaiS,JaraiZ,WagnerJA,GoparajuSK,VargaK,LiuJ,WangL,MirshahiF,KhanolkarAD,
Makriyannis A, Urbaschek R, Garcia N Jr, Sanyal AJ, Kunos G (2001) Endocannabinoids
actingatvascularCB1receptorsmediatethevasodilatedstateinadvancedlivercirrhosis.
Nat Med 7:827–832
Beltramo M, Piomelli D (2000) Carrier-mediated transport and enzymatic hydrolysis of the
endogenous cannabinoid 2-arachidonylglycerol. Neuroreport 11:1231–1235
Beltramo M, Stella N, Calignano A, Lin SY, Makriyannis A, Piomelli D (1997) Functional
role of high-affinity anandamide transport, as revealed by selective inhibition. Science
277:1094–1097
Ben-Shabat S, Fride E, Sheskin T, Tamiri T, Rhee MH, Vogel Z, Bisogno T, De Petrocellis L,
Di Marzo V, Mechoulam R (1998) An entourage effect: inactive endogenous fatty acid
glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity. Eur J Pharmacol
353:23–31